The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The
thromboembolism risk is especially high in patients with chronic obstructive pulmonary
disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration
of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and
bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of
prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital